Akari Therapeutics, Plc Board of Directors

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Dr. Samir Rashmikant Patel M.D.

Dr. Samir Rashmikant Patel M.D.

Interim President, CEO & Director

Dr. Miles Nunn

Dr. Miles Nunn

Chief Scientific Officer

Ms. Wendy F. DiCicco CPA

Ms. Wendy F. DiCicco CPA

Interim Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.